Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

Around 10 SARS-CoV-2 virions per cell in human body, study finds

A new study has found that there are about ten virus particles in each cell in the body. The research team from the Weizmann Institute of Science in Israel and the University of California in the USA estimate that each infected person carries around 109-1011 virions during peak infection.

18 Nov 2020

Natural products and herbal medicines show promise in fight against COVID-19

Researchers in China and the United States have called for more research into the potential prophylactic effects of natural products and herbal medicines on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent coronavirus disease 2019 (COVID-19).

17 Nov 2020

SARS-CoV-2-specific IgM / IgG responses accurately predict COVID-19 outcome

Researchers from the Huazhong University of Science and Technology and Shanghai Jiao Tong University, China, recently built a proteome microarray with 20 out of the 28 predicted SARS-CoV-2 proteins to help understand IgM/IgG responses specific to SARS-CoV-2.

17 Nov 2020

Researchers report encouraging results from in vitro combination therapy against COVID-19

Researchers at Karolinska Institutet in Sweden report promising results from an in vitro combination therapy against COVID-19.

17 Nov 2020

Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2

Researchers in France have conducted a study showing that people who are asymptomatic following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – elicit a polyfunctional antibody response to the virus.

16 Nov 2020

Metabolic biomarkers could predict COVID-19 severity

A new study suggests that metabolic biomarkers could possibly predict the severity of COVID-19 in patients.

16 Nov 2020

Goblet cells are prime target for SARS-CoV-2, study finds

A recent study reports that in the airway of patients with chronic obstructive pulmonary disease (COPD), a type of airway epithelial cell – called a goblet cell – presents a prime target for the virus and plays a vital role in promoting viral replication in this tissue.

16 Nov 2020

Xylitol and grapefruit seed extract nasal spray could help COVID-19 patients

United States based researchers have published a report exploring the potential role of Xylitol and Grapefruit seed extract (in the form of a nasal spray) in treating COVID-19.

16 Nov 2020

New methodology predicts mutation hotspots in SARS-CoV-2 virus

Researchers in Sweden and China have presented a new methodology for predicting mutation “hotspot” sites within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

15 Nov 2020

Dopamine-release mechanisms in the brain may play a major role in SARS-CoV-2 infection

The study, which appeared in the Journal of Taibah University Medical Sciences, shows that the SARS-CoV-2 may behave akin to the CNS pathogenic mechanism of JEV and HIV during the early stages of infection.

15 Nov 2020

Ultrasound reveals a possible role of SARS‐CoV‐2 in acute testicular infection

A single-center study from Wuhan in China presents ultrasound imaging evidence supporting the notion that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause infection of the testis or epididymis – and put patients at risk for further complications. The paper can be found in the Journal of Ultrasound in Medicine.

15 Nov 2020

Novel mutations in SARS-CoV-2 may explain high pathogenicity of COVID-19

Researchers in Korea and the United States have identified novel genetic variants that demonstrate the active mutational progression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

15 Nov 2020

Bispecific sybodies show potential against SARS-CoV-2

As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November 2020 discusses the role of synthetic nanobodies or sybodies in neutralizing the virus by binding to its receptor-binding domain (RBD) on the spike protein.

12 Nov 2020

SARS-CoV-2-induces temporary loss of smell in mice

Now, a new study published on the preprint server bioRxiv in November 2020 presents the onset of olfactory dysfunction (loss of smell) in mice infected with the virus, examining this process at the cellular level. In doing so, this study throws more light on this curious symptom and COVID-19’s manifestations outside the lungs.

12 Nov 2020

Researchers assess risks posed by SARS-CoV-2 to Antarctica wildlife

Researchers have assessed risks posed by the ongoing COVID-19 pandemic on Antarctica wildlife.

12 Nov 2020

Rhesus monkeys and cats potential spillover reservoirs for COVID-19 virus

A team of researchers from Switzerland, Costa Rica and Germany has conducted a study showing which animal species could potentially serve as spillback reservoirs of severe acute repertory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

12 Nov 2020

Low prevalence of SARS-CoV-2 specific antibodies in Lubbock, Texas

A recent study published in the Journal of Primary Care and Community Health has assessed the prevalence of antibodies developed specifically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in front-line workers in Lubbock, Texas. According to the study findings, immunoglobulin G (IgG)-specific anti-SARS-CoV-2 antibodies have been detected in only 0.73% of the participants.

11 Nov 2020

Nafamostat mesylate initially reduces SARS-CoV-2 viral loads in hamsters, study finds

Researchers have found that nafamostat mesylate, when injected in the nasal cavity of Syrian hamsters, can decrease initial SARS-CoV-2 viral loads in their nose. However, this effect was temporary and further testing is required to determine clinically significant effects. The research group's findings are available on the preprint server bioRxiv*.

11 Nov 2020

Endothelial cells resistant to SARS-CoV-2 infection

A team of scientists from Imperial College London has conducted a series of in vitro studies to investigate the susceptibility of endothelial cells to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative pathogen of coronavirus disease 2019 (COVID-19).

10 Nov 2020

Identifying SARS-CoV-2 spike protein mutations resistant to antibodies

Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies.

10 Nov 2020